|Bid||15.99 x 1800|
|Ask||16.12 x 900|
|Day's Range||15.60 - 16.16|
|52 Week Range||3.12 - 20.57|
|Beta (5Y Monthly)||2.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.05|
NEW YORK, July 21, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug.
A look at the shareholders of Mesoblast Limited (ASX:MSB) can tell us which group is most powerful. Generally...
Mesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance's On the Move to discuss what this development could mean in the fight against the virus.